New Listing News | GenHouse Bio Submits Application to Hong Kong Stock Exchange

Stock News01-18

GenHouse Bio (Suzhou) Co., Ltd. - B submitted a listing application to the main board of the Hong Kong Stock Exchange on January 16, with Huatai International acting as its sole sponsor. According to the prospectus, as of January 7, 2026, the company's pipeline includes seven self-developed drug candidates. This pipeline comprises four candidates in the clinical stage, one candidate that has received IND approvals from China's NMPA and the U.S. FDA, and two candidates in the preclinical stage. The company is a biopharmaceutical firm with a differentiated and robust pipeline of self-developed innovative drug candidates built around the RAS signaling pathway and synthetic lethality mechanisms. According to data from CIC, several of the company's candidates are globally leading in terms of clinical progress for the same targets. The company primarily focuses on developing potential best-in-class targeted therapies in the field of oncology. Since its establishment in 2014, the company has leveraged its expertise and insights in translational medicine to drive continuous innovation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150929748?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-18 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150929748","market":"nz","top_or_hot":-1,"title":"New Listing News | GenHouse Bio Submits Application to Hong Kong Stock Exchange","media":"Stock News","content":"<p>GenHouse Bio (Suzhou) Co., Ltd. - B submitted a listing application to the main board of the Hong Kong Stock Exchange on January 16, with Huatai International acting as its sole sponsor. According to the prospectus, as of January 7, 2026, the company's pipeline includes seven self-developed drug candidates. This pipeline comprises four candidates in the clinical stage, one candidate that has received IND approvals from China's NMPA and the U.S. FDA, and two candidates in the preclinical stage. The company is a biopharmaceutical firm with a differentiated and robust pipeline of self-developed innovative drug candidates built around the RAS signaling pathway and synthetic lethality mechanisms. According to data from CIC, several of the company's candidates are globally leading in terms of clinical progress for the same targets. The company primarily focuses on developing potential best-in-class targeted therapies in the field of oncology. Since its establishment in 2014, the company has leveraged its expertise and insights in translational medicine to drive continuous innovation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Listing News | GenHouse Bio Submits Application to Hong Kong Stock Exchange</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Listing News | GenHouse Bio Submits Application to Hong Kong Stock Exchange\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-18 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GenHouse Bio (Suzhou) Co., Ltd. - B submitted a listing application to the main board of the Hong Kong Stock Exchange on January 16, with Huatai International acting as its sole sponsor. According to the prospectus, as of January 7, 2026, the company's pipeline includes seven self-developed drug candidates. This pipeline comprises four candidates in the clinical stage, one candidate that has received IND approvals from China's NMPA and the U.S. FDA, and two candidates in the preclinical stage. The company is a biopharmaceutical firm with a differentiated and robust pipeline of self-developed innovative drug candidates built around the RAS signaling pathway and synthetic lethality mechanisms. According to data from CIC, several of the company's candidates are globally leading in terms of clinical progress for the same targets. The company primarily focuses on developing potential best-in-class targeted therapies in the field of oncology. Since its establishment in 2014, the company has leveraged its expertise and insights in translational medicine to drive continuous innovation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1150929748","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150929748","pubTimestamp":1768739781,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GenHouse Bio (Suzhou) Co., Ltd. - B submitted a listing application to the main board of the Hong Kong Stock Exchange on January 16, with Huatai International acting as its sole sponsor. According to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1515":"抗疫概念","09939":"开拓药业-B","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"上市新动态|GenHouse Bio向港交所递交申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"HEXmain":1},"content_text":"GenHouse Bio (Suzhou) Co., Ltd. - B submitted a listing application to the main board of the Hong Kong Stock Exchange on January 16, with Huatai International acting as its sole sponsor. According to the prospectus, as of January 7, 2026, the company's pipeline includes seven self-developed drug candidates. This pipeline comprises four candidates in the clinical stage, one candidate that has received IND approvals from China's NMPA and the U.S. FDA, and two candidates in the preclinical stage. The company is a biopharmaceutical firm with a differentiated and robust pipeline of self-developed innovative drug candidates built around the RAS signaling pathway and synthetic lethality mechanisms. According to data from CIC, several of the company's candidates are globally leading in terms of clinical progress for the same targets. The company primarily focuses on developing potential best-in-class targeted therapies in the field of oncology. Since its establishment in 2014, the company has leveraged its expertise and insights in translational medicine to drive continuous innovation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150929748","isCrawlerRequest":true}